
Jan 8 (Reuters) - Acrivon Therapeutics Inc ACRV.O:
ACRIVON THERAPEUTICS ANNOUNCES POSITIVE ACR-368 PHASE 2B ENDOMETRIAL CANCER CLINICAL DATA WITH EU EXPANSION TO ACCELERATE ENROLLMENT, INITIAL ACR-2316 CLINICAL DATA, AND ACR-6840, ITS NEXT AP3-ENABLED DEVELOPMENT CANDIDATE, TARGETING CDK11
ACRIVON THERAPEUTICS INC - ACR-2316 PHASE 1 SHOWS FAVORABLE TOLERABILITY
ACRIVON THERAPEUTICS INC: ACR-6840 IND SUBMISSION PLANNED FOR Q4 2026